Susquehanna International Group, LLP Aldeyra Therapeutics, Inc. Call Options Transaction History

Susquehanna International Group, LLP

$560 Billion
Q3 2024

Call Options

27 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$3.19 - $6.32 $40,194 - $79,632	12,600 Added 19.35%	77,700 $418,000
Q2 2024 Aug 15, 2024	BUY	$3.25 - $4.72 $147,225 - $213,816	45,300 Added 228.79%	65,100 $215,000
Q1 2024 May 07, 2024	SELL	$2.77 - $4.22 $66,757 - $101,702	-24,100 Reduced 54.9%	19,800 $64,000
Q4 2023 Feb 14, 2024	BUY	$1.47 - $6.06 $37,191 - $153,318	25,300 Added 136.02%	43,900 $154,000
Q3 2023 Nov 14, 2023	SELL	$6.11 - $8.16 $16,497 - $22,032	-2,700 Reduced 12.68%	18,600 $124,000
Q2 2023 Aug 11, 2023	SELL	$7.11 - $11.89 $1 Million - $1.68 Million	-141,300 Reduced 86.9%	21,300 $178,000
Q1 2023 May 16, 2023	BUY	$5.77 - $9.93 $466,215 - $802,344	80,800 Added 98.78%	162,600 $1.61 Million
Q4 2022 Feb 14, 2023	BUY	$5.08 - $7.09 $147,828 - $206,319	29,100 Added 55.22%	81,800 $569,000
Q3 2022 Nov 14, 2022	SELL	$3.8 - $7.74 $85,120 - $173,376	-22,400 Reduced 29.83%	52,700 $281,000
Q2 2022 Aug 15, 2022	SELL	$2.43 - $4.85 $534,114 - $1.07 Million	-219,800 Reduced 74.53%	75,100 $300,000
Q1 2022 May 16, 2022	SELL	$3.25 - $5.17 $197,275 - $313,819	-60,700 Reduced 17.07%	294,900 $1.31 Million
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $977,900 - $2.69 Million	279,400 Added 366.67%	355,600 $1.42 Million
Q3 2021 Nov 15, 2021	SELL	$7.94 - $11.31 $302,514 - $430,911	-38,100 Reduced 33.33%	76,200 $669,000
Q2 2021 Aug 11, 2021	SELL	$10.44 - $14.85 $991,800 - $1.41 Million	-95,000 Reduced 45.39%	114,300 $1.3 Million
Q1 2021 May 17, 2021	BUY	$6.53 - $14.42 $931,831 - $2.06 Million	142,700 Added 214.26%	209,300 $2.49 Million
Q4 2020 Feb 16, 2021	SELL	$6.31 - $8.13 $142,606 - $183,738	-22,600 Reduced 25.34%	66,600 $457,000
Q3 2020 Nov 16, 2020	BUY	$4.0 - $7.53 $191,600 - $360,687	47,900 Added 115.98%	89,200 $661,000
Q2 2020 Aug 14, 2020	BUY	$1.97 - $5.05 $60,085 - $154,025	30,500 Added 282.41%	41,300 $172,000
Q1 2020 May 15, 2020	SELL	$1.62 - $6.4 $39,852 - $157,440	-24,600 Reduced 69.49%	10,800 $27,000
Q4 2019 Feb 14, 2020	BUY	$4.73 - $7.98 $120,142 - $202,692	25,400 Added 254.0%	35,400 $206,000
Q3 2019 Nov 14, 2019	SELL	$4.41 - $6.12 $156,114 - $216,648	-35,400 Reduced 77.97%	10,000 $53,000
Q2 2019 Aug 14, 2019	SELL	$6.0 - $9.0 $73,200 - $109,800	-12,200 Reduced 21.18%	45,400 $272,000
Q1 2019 May 15, 2019	BUY	$7.14 - $9.85 $61,404 - $84,710	8,600 Added 17.55%	57,600 $520,000
Q4 2018 Feb 14, 2019	BUY	$7.26 - $13.29 $147,378 - $269,787	20,300 Added 70.73%	49,000 $407,000
Q3 2018 Nov 14, 2018	BUY	$6.8 - $14.35 $195,160 - $411,845	28,700 New	28,700 $396,000
Q2 2018 Aug 14, 2018	SELL	$6.95 - $9.18 $295,375 - $390,150	-42,500 Closed	0 $0
Q1 2018 May 15, 2018	BUY	$6.55 - $8.9 $278,375 - $378,250	42,500 New	42,500 $319,000

Others Institutions Holding ALDX

# of Institutions

117

Shares Held

36.4M

Call Options Held

196K

Put Options Held

142K

Perceptive Advisors LLC New York, NY

9.28M
Shares

$39.1 Million
1.31% of portfolio
Knoll Capital Management, LLC Miami, FL

5.48M
Shares

$23.1 Million
14.56% of portfolio
Vanguard Group Inc Valley Forge, PA

3.76M
Shares

$15.8 Million
0.0% of portfolio
Black Rock Inc. New York, NY

3.62M
Shares

$15.2 Million
0.0% of portfolio
Kennedy Capital Management, Inc. St Louis, MO

1.88M
Shares

$7.92 Million
0.24% of portfolio

View Full List

About Aldeyra Therapeutics, Inc.

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $246M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

More about ALDX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.

Account